Medical Device Media Reporting Pioneer
Share Professional Medical Device Knowledge
Source:Instrument Family,Reproduction without authorization is prohibited, and reproduction is allowed 24 hours later.
October 9,Johnson & Johnson announced plans to invest more than $2 billion (approximatelyRMB 14.1 billion) Build an advanced biologics manufacturing facility,To support its growing portfolio of biologic therapies in the fields of oncology, immunology, and neuroscience.
It is reported that this move aligns with Johnson & Johnson's broader strategy to submit or launch more than 70 new therapies and product expansions by the end of the next decade.The new facility will be equipped with cutting-edge technology and, in addition to enhancing global production capacity, will provide approximately 420 high-skilled full-time positions locally.The project will begin construction in the first half of 2025.
In August this year, to strengthen its position in the cardiovascular field, Johnson & Johnson announced the acquisition of V-Wave, a company specializing in heart failure treatment technology. Prior to this, in April, Johnson & Johnson made an acquisition for approximately $13.1 billion, which will reshape the treatment landscape for cardiovascular diseases.
Some analysts believe that,Johnson & Johnson may continue to increase its investment in the biopharmaceutical and cardiovascular fields, constantly expanding its product lines and market share through innovation in research and development as well as acquisitions and integration.There may be more M&A deals in the future to achieve resource integration and technological innovation, enhancing the competitiveness of enterprises.
Johnson & Johnson Invests an Additional $2 Billion
Dapo Ajayi, Vice President of Johnson & Johnson's Innovative Medicine Supply Chain, stated: "A robust global supply chain is crucial, and we are making targeted investments to ensure our transformative medicines reach patients around the world reliably and efficiently." "We are investing in capacity and new technologies to enhance our industry-leading capabilities and ensure a resilient supply chain for the future."
According to reports,The new facility will be equipped with cutting-edge technology to streamline and optimize the biologics manufacturing process. In addition to enhancing the company's global production capacity, the Wilson plant will employ approximately 420 full-time staff in highly skilled positions. Johnson & Johnson considers North Carolina a key region for biopharmaceutical manufacturing., thanks to a well-developed life science ecosystem and abundant local talent.
The project is scheduled to commence construction in the first half of 2025, with plans to significantly expand the company's manufacturing operations to meet growing demand.Once operational, the facility is expected to play a key role in supporting Johnson & Johnson's long-term pipeline and product launch objectives, while also contributing to the state's growing life sciences industry.
"North Carolina is an important biopharmaceutical manufacturing and talent hub, and we are excited to join this thriving life sciences ecosystem as part of the Wilson community."Dapo AjayiAdded remarks.
Johnson & Johnson Increases InvestmentThe Meaning of InvestmentIt is worth mentioning that,In August this year, to strengthen its position in the cardiovascular field, Johnson & Johnson announced the acquisition of V-Wave, a company specializing in heart failure treatment technologies.Prior to this, Johnson & Johnson's acquisition in April for approximately $13.1 billion will reshape the treatment landscape for cardiovascular diseases.
For Johnson & Johnson, this investment in North Carolina will help enhance its competitiveness in the biopharmaceutical field, meet the growing market demand, and achieve its long-term product development strategy. Meanwhile,By acquiring V-Wave and Shockwave Medical, Johnson & Johnson further strengthened its position in the cardiovascular field and expanded its business scope.
For North Carolina,Johnson & Johnson's investment will bring a large number of job opportunities to the local area, promote the development of the life sciences industry, and drive local economic growth.For the entire industry, Johnson & Johnson's large-scale investments and acquisitions may intensify competition within the sector. Other pharmaceutical companies might increase their R&D and investment efforts in biopharmaceuticals and cardiovascular fields to maintain competitiveness. This could also promote innovation and development of related technologies, driving advancements in biopharmaceuticals and cardiovascular treatments.Some analyses believe,Johnson & Johnson will continue to increase its investment in the biopharmaceutical and cardiovascular fields, constantly expanding its product lines and market share through innovation in research and development as well as acquisitions and integration.FutureThere may be more M&A deals within the industry to achieve resource integration and technological innovation, enhancing the competitiveness of enterprises.
Johnson & Johnson's Development StrategyPublic information shows that Johnson & Johnson, established in 1886, is one of the most comprehensive healthcare enterprises with a wide range of business operations globally.Business spans three major fields: medical devices, pharmaceuticals, and consumer goods.. At present, the development strategy of Johnson & Johnson is mainly reflected inBusiness layout adjustment and focus, innovation-driven, mergers and acquisitions expansion, global market expansion, digital transformation, and sustainable developmentand other aspects.Business Layout Adjustment and Focus
Business SplitIn 2021, Johnson & Johnson announced that it would spin off its consumer health business into a separate publicly traded company, separating it from the existing pharmaceuticals business.The new Johnson & Johnson remains a diversified pharmaceutical and medical device enterprise, while the new consumer health company is more focused on the consumer products sector.This move enables the two companies to conduct business more targetedly, improving operational efficiency and competitiveness.Focus on Key R&D Areas: Since last year,Johnson & Johnson Gradually Phases Out Cardiopulmonary and Metabolic Work, Focusing R&D on Oncology, Immunology, and NeuroscienceThese three fields have broad market prospects and unmet medical needs. By increasing R&D investment in these areas, Johnson & Johnson is expected to launch more innovative drugs and treatment solutions, securing a leading position in the market.Innovation-Driven
R&D Investment: Johnson & Johnson has always attached great importance to R&D innovation.Continuously invest funds in the development of new products and the improvement of existing products.For example, in China, Johnson & Johnson was the first multinational company to successfully implement an "end-to-end" R&D model.Johnson & Johnson has established R&D institutions in all three major business areas in China, and set up the Johnson & Johnson Asia-Pacific Innovation Center in Shanghai to accelerate the development of innovative products in China.Open Innovation: Johnson & Johnson actively builds an innovative ecosystem. For example, in 2019, it established a one-stop collaborative innovation platform, JLABS, in Shanghai. As one of Johnson & Johnson's four global open innovation platforms, it combines the company’s resources, expertise, and regional advantages in China, the Asia-Pacific region, and globally to support the development of local startups and bring breakthrough healthcare solutions to the global market.M&A Expansion
Cardiovascular Field Layout：In recent years, Johnson & Johnson has been strengthening its position in the细分 cardiovascular market through significant acquisitions.In November 2022, Johnson & Johnson acquired Abiomed, a leader in heart recovery, for $16.6 billion; in November 2023, Johnson & Johnson acquired Laminar for a $400 million upfront payment, whose left atrial appendage closure technology is used to treat non-valvular atrial fibrillation; in 2023, Johnson & Johnson acquired Shockwave for $13.1 billion, the world's first company to provide intravascular lithotripsy for coronary arteries. These acquisitions expanded Johnson & Johnson’s product portfolio and technical capabilities in the cardiovascular intervention field.Acquisitions in Other Fields: 2024,Johnson & Johnson Completes Acquisition of All Outstanding Shares of U.S. Innovative Drug Company Ambrx BiopharmaTo strengthen its capabilities in the biopharmaceutical field.Global Market Expansion
Strengthening the Layout in the Chinese Market: China is one of the fastest-growing markets for Johnson & Johnson's global business, and the company continues to increase its investment and business expansion in China. For example,Johnson & Johnson has established more than 10 legal entities in China, with supply chain bases located in cities such as Beijing, Shanghai, Guangzhou, Suzhou, and Xi'an. Meanwhile, Johnson & Johnson actively promotes Chinese innovation to global markets, introducing products developed in China to international markets.Expansion into other regional markets: Johnson & Johnson has established more than 250 branches in 60 countries worldwide, with products sold in 175 countries and regions.By continuously expanding into global markets, the company increases its business coverage and market share.Digital Transformation
Johnson & Johnson proposed the strategy of "Building a Digital Ecosystem, Reshaping the Future of Health," integrating big data, artificial intelligence, robotic surgery technology, and other healthcare businesses to construct a digital ecosystem. This achieves innovation empowerment, marketing empowerment, and operational empowerment, accelerates the innovation process and achievement transformation, enhances brand awareness, and improves operational efficiency.Sustainable Development
Johnson & Johnson commits to invest 800 million US dollars by 2030 to improve human and planetary health, with specific measures including enhancing transparency of product ingredients, reducing reliance on plastic packaging, and raising awareness about safe sun protection.Focus on achieving sustainable development while growing the business.In recent years, due to the constantly changing global market environment, multinational device companies have been accelerating adjustments and transformations to enhance competitiveness.From 2023 to the present, the global technology industry has remained under the pressure of an economic downturn, and medical technology is no exception. Against this backdrop, "cost reduction and efficiency enhancement" have become inevitable measures for corporate survival, with a series of actions such as layoffs, pay cuts, spin-offs, business adjustments, and the scaling back of employee benefits taking place in succession.
Among these, Johnson & Johnson has never stopped its innovative transformation步伐 through various methods such as spin-offs, reorganizations, and mergers and acquisitions.So, what's next? How will Johnson & Johnson achieve strong, sustained growth? Medical Device News will continue to follow up.
More exciting content
Welcome to follow WeChat Video Channel
BusinessBusiness cooperation email: qxzj@landianyiliao.com
